| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
136,480,000 |
| Market
Cap: |
4.48(B) |
| Last
Volume: |
503,160 |
Avg
Vol: |
501,762 |
| 52
Week Range: |
$26.23 - $39.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P 400 MIDCAP |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Perrigo is a provider of over-the-counter health and wellness solutions that can be self-managed. Co.'s segments are as follows: Consumer Self-Care Americas, which is focused primarily on the sale of self-care products in categories including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements; Consumer Self-Care International, which develops, manufactures, markets, and distributes European consumer self-care brands in the upper respiratory, pain and sleep-aids, digestive health, vitamins, minerals and supplements; and Prescription Pharmaceuticals, which develops, manufactures, and markets a portfolio of generic prescription drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Farrington Thomas |
Senior VP and CIO |
• • – |
2013-12-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,098) |
0 |
|
- |
|
| Farrington Thomas |
Senior VP and CIO |
• • – |
2013-12-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,040) |
0 |
|
- |
|
| Brown Judy L |
Executive VP & CFO |
• • – |
2013-12-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(7,445) |
0 |
|
- |
|
| Boothe Douglas |
EVP & GM Perrigo Pharma |
• • – |
2013-12-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(1) |
0 |
|
- |
|
| Papa Joseph C |
President and CEOChairman |
• • – |
2013-12-12 |
4 |
AS |
$149.43 |
$2,251,819 |
D/D |
(15,000) |
116,655 |
|
- |
|
| Papa Joseph C |
President and CEOChairman |
• • – |
2013-12-12 |
4 |
OE |
$30.06 |
$728,401 |
D/D |
15,000 |
125,506 |
|
- |
|
| Cohen Gary M |
Director |
• • – |
2013-12-12 |
4 |
S |
$152.52 |
$706,473 |
D/D |
(4,632) |
11,868 |
|
- |
|
| Papa Joseph C |
President and CEOChairman |
• • – |
2013-12-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
96,655 |
|
- |
|
| Jandernoa Michael J |
Director |
• • – |
2013-12-09 |
4 |
S |
$154.97 |
$10,634,213 |
I/I |
(68,620) |
120,552 |
|
- |
|
| Jandernoa Michael J |
Director |
• • – |
2013-12-06 |
4 |
S |
$155.67 |
$9,339,918 |
I/I |
(60,000) |
148,000 |
|
- |
|
| Yu Louis |
Executive VP Global Quality |
• • – |
2013-12-05 |
4 |
S |
$155.22 |
$10,865 |
I/I |
(70) |
5,420 |
|
- |
|
| Cohen Gary M |
Director |
• • – |
2013-11-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
60 |
16,500 |
|
- |
|
| Yu Louis |
Executive VP Global Quality |
• • – |
2013-11-25 |
4 |
S |
$155.50 |
$356,422 |
D/D |
(2,292) |
8,548 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• • – |
2013-11-22 |
4 |
S |
$154.97 |
$1,007,312 |
I/I |
(6,500) |
3,000 |
|
- |
|
| Brown Judy L |
Executive VP & CFO |
• • – |
2013-11-21 |
4 |
S |
$154.74 |
$1,545,563 |
I/I |
(9,988) |
0 |
|
- |
|
| Hendrickson John T |
EVP Global Operations & Supply |
• • – |
2013-11-20 |
4 |
S |
$152.80 |
$1,283,544 |
I/I |
(8,400) |
0 |
|
- |
|
| Yu Louis |
Executive VP Global Quality |
• • – |
2013-11-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
5,490 |
5,490 |
|
- |
|
| Yu Louis |
Executive VP Global Quality |
• • – |
2013-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,490 |
3,058 |
|
- |
|
| Kochan Sharon |
Executive VP U.S. Generics |
• • – |
2013-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
450 |
4,636 |
|
- |
|
| Kochan Sharon |
Executive VP U.S. Generics |
• • – |
2013-11-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
450 |
450 |
|
- |
|
| Kochan Sharon |
Executive VP U.S. Generics |
• • – |
2013-11-15 |
4 |
S |
$152.53 |
$69,401 |
D/D |
(455) |
5,086 |
|
- |
|
| Jandernoa Michael J |
Director |
• • – |
2013-11-14 |
4 |
GD |
$0.00 |
$0 |
I/I |
359,600 |
235,901 |
|
- |
|
| Jandernoa Michael J |
Director |
• • – |
2013-11-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
237,500 |
65,500 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• • – |
2013-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
9,500 |
5,892 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• • – |
2013-11-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
9,500 |
9,500 |
|
- |
|
1400 Records found
|
|
Page 2 of 56 |
|
|
0.27 (0.82%) 
